Kennedy's disease, also known as spinal and bulbar muscular atrophy (SBMA), is a rare X-linked recessive neuromuscular disorder characterized by progressive degeneration of motor neurons[1]. Unlike sporadic ALS, Kennedy's disease has a strong genetic basis and follows a more indolent clinical course. The disease primarily affects adult males, with onset typically occurring in the fourth to sixth decade of life[1:1]. This disorder provides important insights into the pathogenesis of motor neuron degeneration and has served as a model for understanding androgen-dependent neuronal toxicity.
Kennedy's disease is caused by a polymorphic CAG trinucleotide repeat expansion in the first exon of the androgen receptor (AR) gene located on the X chromosome (Xq11-12)[2]. This expansion leads to a mutant androgen receptor protein with an elongated polyglutamine (polyQ) tract, which acquires toxic gain-of-function properties[2:1]. The disease is characterized by progressive weakness and atrophy of the bulbar and limb muscles, with relative sparing of respiratory function and cognitive abilities.
The prevalence of Kennedy's disease is estimated at 1-2 per 100,000 males worldwide, though it is likely underdiagnosed due to its resemblance to other motor neuron disorders[3]. Geographic variations exist, with higher prevalence reported in certain populations due to founder effects.
Kennedy's disease is caused by CAG trinucleotide repeat expansions in the androgen receptor (AR) gene:
| Feature | Value |
|---|---|
| Gene | AR (Androgen Receptor) |
| Chromosome | Xq11-12 |
| Mutation | CAG repeat expansion |
| Normal range | 10-36 repeats |
| Disease range | 38-62 repeats |
| Inheritance | X-linked recessive |
The number of CAG repeats broadly correlates with age of onset and disease severity - larger expansions are generally associated with earlier onset and more severe phenotype[4]. However, significant variability exists even among patients with similar repeat lengths, indicating the influence of modifier genes and environmental factors.
The mutant androgen receptor with expanded polyQ tract exerts toxicity through multiple mechanisms:
Transcriptional dysregulation: The mutant AR interferes with normal transcriptional regulation, affecting genes involved in neuronal survival and function[5].
Proteasomal dysfunction: Aggregated mutant AR protein overwhelms cellular protein quality control systems[6].
Mitochondrial dysfunction: Energy production deficits and increased oxidative stress in motor neurons[7].
Loss of normal AR function: Partial loss of androgen receptor signaling may contribute to neuronal vulnerability[8].
Excitotoxicity: Enhanced sensitivity to glutamate-induced excitotoxicity[9].
The disease exhibits striking androgen-dependence - male hormones (testosterone, dihydrotestosterone) accelerate disease progression, while strategies to reduce androgen activity (including surgical castration in affected individuals) have shown benefit[10].
| Symptom | Frequency | Description |
|---|---|---|
| Progressive limb weakness | >95% | Proximal more than distal, lower limbs initially |
| Muscle atrophy | >90% | Visible wasting, particularly in thighs and shoulders |
| Bulbar symptoms | 70-85% | Dysphagia, dysarthria, tongue fasciculations |
| Tremor | 50-70% | Postural tremor, often fine and distal |
| Muscle cramps | 40-60% | Painful involuntary contractions |
| Fasciculations | 60-80% | Visible muscle twitches, particularly in tongue |
| Fatigue | 50-70% | Exercise intolerance and easy fatigability |
The diagnosis is suspected based on:
Gold standard: Molecular genetic testing for CAG repeat expansion in the AR gene[11]
Kennedy's disease must be distinguished from:
Currently, no cure or disease-modifying therapy has been definitively proven to alter disease progression. Several approaches are under investigation:
Androgen reduction therapy:
ASOs and gene therapy:
Neuroprotective agents:
Kennedy's disease has a significantly better prognosis than ALS:
Several animal models have been developed:
Kennedy's disease: challenges in diagnosis and treatment. Finsterer J, et al. J Neurol Sci. 2020. 2020. ↩︎ ↩︎
Androgen receptor CAG repeat length and X-inactivation in SBMA. Schmidt BJ, et al. Neurology. 2002. 2002. ↩︎ ↩︎
Prevalence of Kennedy disease in Finland. Laaksonen AL, et al. J Neurol. 2021. 2021. ↩︎
CAG repeat length and phenotype in SBMA. Date MD, et al. Neurology. 2001. 2001. ↩︎
Transcriptional dysregulation in SBMA. Katsuno M, et al. Ann Neurol. 2006. 2006. ↩︎
Mutant androgen receptor protein aggregation in SBMA. Walcott JL, et al. J Biol Chem. 2018. 2018. ↩︎
Mitochondrial dysfunction in SBMA. Ranganathan S, et al. Exp Neurol. 2009. 2009. ↩︎
Androgen receptor function in motor neurons. Garland JS, et al. J Mol Neurosci. 2008. 2008. ↩︎
Excitotoxicity in SBMA. Giagnoni E, et al. Neurobiol Dis. 2015. 2015. ↩︎
Androgen deprivation therapy in SBMA. Banno H, et al. Lancet Neurol. 2009. 2009. ↩︎ ↩︎ ↩︎
Genetic testing for SBMA: recommendations. Prior TW, et al. Neurology. 2007. 2007. ↩︎
Electromyography in SBMA. Ferran B, et al. Clin Neurophysiol. 2020. 2020. ↩︎
Dutasteride therapy in SBMA. Fischbeck KH, et al. Neurology. 2011. 2011. ↩︎
Antisense oligonucleotide therapy for SBMA. Liu J, et al. Nat Med. 2017. 2017. ↩︎
RNAi gene therapy for SBMA. Ohsawa Y, et al. Mol Ther. 2018. 2018. ↩︎
Minocycline trial in SBMA. Pal PK, et al. Neurology. 2005. 2005. ↩︎
Lithium therapy in SBMA. Yang Y, et al. J Neurol Neurosurg Psychiatry. 2017. 2017. ↩︎
Stem cell therapy for motor neuron disease. Glass JD, et al. Neurology. 2016. 2016. ↩︎
Transgenic SBMA mouse model. Abel A, et al. Neuron. 2001. 2001. ↩︎
Knock-in SBMA mouse model. Chevalier-Larsen ES, et al. J Neurosci. 2014. 2014. ↩︎
C. elegans model of SBMA. Faber PW, et al. Hum Mol Genet. 1999. 1999. ↩︎
Drosophila model of SBMA. Takeyama K, et al. Cell. 2002. 2002. ↩︎